Synthesis, antitubercular activity, and QSAR analysis of substituted nitroaryl analogs: Chalcone, pyrazole, isoxazole, and pyrimidines

Medicinal Chemistry Research

Volumn 22, Issue 8, 2013, Pages 3863-3880

  Gupta, Revathi A ^a   Kaskhedikar, Satish G ^a  

^a SHRI G S INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Antimycobacterial; Chalcones; QSAR; SQ MLR; Tuberculosis

Indexed keywords

3 (2,4 DIMETHOXYPHENYL) 1 (4 NITROPHENYL)PROP 2 EN 1 ONE; 3 (2,5 DIMETHOXYPHENYL) 1 (4 NITROPHENYL)PROP 2 EN 1 ONE; 3 (3 CHLOROPHENYL) 1 (4 NITROPHENYL)PROP 2 EN 1 ONE; 3 (3 METHOXYPHENYL) 1 (4 NITROPHENYL)PROP 2 EN 1 ONE; 3 (3,4 DIMETHOXYPHENYL) 1 (4 NITROPHENYL)PROP 2 EN 1 ONE; 3 (3,4,5 TRIMETHOXYPHENYL) 1 (4 NITROPHENYL)PROP 2 EN 1 ONE; 3 (4 CHLOROPHENYL) 1 (4 NITROPHENYL)PROP 2 EN 1 ONE; 3 (4 FLUOROPHENYL) 1 (4 NITROPHENYL)PROP 2 EN 1 ONE; 3 (4 METHOXYPHENYL) 1 (4 NITROPHENYL)PROP 2 EN 1 ONE; 5 (2,4 DIMETHOXYPHENYL) 3 (4 NITROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 5 (2,5 DIMETHOXYPHENYL) 3 (4 NITROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 5 (3 CHLOROPHENYL) 3 (4 NITROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 5 (3 METHOXYPHENYL) 3 (4 NITROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 5 (3,4 DIMETHOXYPHENYL) 3 (4 NITROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 5 (4 BROMOPHENYL) 3 (4 NITROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 5 (4 CHLOROPHENYL) 3 (4 NITROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 5 (4 FLUOROPHENYL) 3 (4 NITROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 5 (4 METHOXYPHENYL) 3 (4 NITROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 5 (4 NITROPHENYL) 3 (4 NITROPHENYL) 4,5 DIHYDRO 1H PYRAZOLE; 6 (3 METHOXYPHENYL) 4 (4 NITROPHENYL) 5,6 DIHYDROPYRIMIDIN 2 (1H)ONE; 6 (4 METHOXYPHENYL) 4 (4 NITROPHENYL) 5,6 DIHYDROPYRIMIDIN 2 (1H)ONE; CHALCONE DERIVATIVE; ETHAMBUTOL; ISONIAZID; ISOXAZOLE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SYNTHESIS; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROCESS OPTIMIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 84879506191     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0385-3     Document Type: Article

References (47)

1. Akaike H (1973) Information theory and an extension of the minimum likelihood principle. Akademiai Kiado, Budapest, pp 267-281
2. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Autom Control 19:716-723
3. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, Drucker E, Bloom BR (1994) Transmission of tuberculosis in New York city - an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med 330:1710-1716
4. Bryant D, McCalla D, Leeksma M, Laneuville P (1981) Type I nitroreductases of Escherichia coli. Can J Microbiol 27:81-86
5. Chatterjee S, Hadi A, Price B (2000) Regression analysis by examples, 3rd edn. Wiley, New York
6. Churkin YD, Panfilova LV, Boreko EI (1982) Synthesis and antiviral activity of unsaturated ketones of thiopene series. Pharm Chem 16:103-105
7. Corbett EL, Watt CJ, Walker N, Maher BMD, Williams BG, Raviglione MC, Dye C (2003) The growing burden of tuberculosis - global trends and interactions with the HIV epidemic. Arch Intern Med 163:1009-1021
8. CS ChemOffice (2000) Version 6.0, Cambridge Soft Corporation, Software Publishers Association, 1730 M Street, Suite 700, Washington DC. 20036 (202) 452-1600, USA
9. Duncan K (2003) Progress in TB drug development and what is still needed. Tuberculosis 83:201-207
10. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC (1999) Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 282:677-686
11. Edwards DI (1993) Nitroimidazole drugs-action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 31:9-20
12. Friedman J (1990) Multivariate adaptive regression splines. Technical Report No. 102. Laboratory for Computational Statistics. Stanford University, Stanford
13. Global Alliance for TB Drug Development (2001) Scientific blueprint for tuberculosis drug development. Tuberculosis 81 (Suppl. 1):1-52
14. Gupta RA, Kaskhedikar SG (2011) Insights into the structural requirement of 6-nitroquinolone-3-carboxylic acids as antimycobacterial agent: chemometric approaches. Med Chem Res. doi: 10.1007/s00044-011-9930-8
15. Gupta AK, Babu MA, Kaskhedikar SG (2004) VALSTAT: validation program for quantitative structure activity relationship studies. Indian J Pharm Sci 66:396-402
16. Gupta AK, Gupta RA, Soni LK, Kaskhedikar SG (2008) Exploration of physicochemical properties and molecular modelling studies of 2-sulfonyl-phenyl-3-phenyl-indole analogs as cyclooxygenase-2 inhibitors. Eur J Med Chem 43:1297-1303
17. Gupta AK, Sabarwal N, Agrawal YP, Prachand S, Jain S (2010) Insights through AM1 calculations into the structural requirement of 3,4,6-substituted-2- quinolone analogs towards FMS kinase inhibitory activity. Eur J Med Chem 45:3472-3479
18. Hansch C, Leo A (1995) Exploring QSAR, fundamentals and applications in chemistry and biology. American Chemical Society, Washington, DC, pp 90-100
19. Jacobs RF (1994) Multiple drug resistant tuberculosis. Clin Infect Dis 19:1-10
20. Jevwon S, Liv CT, Sao LT, Weng JR, Ko HH (2005) Synthetic chalcones as potential anti-inflammatory and cancer chemopreventive agents. Eur J Med Chem 40:103-112
21. Kaplancikli ZA, Turan-Zitouni G, Ozdemir A, Revial G (2008) New triazole and triazolothiadiazine derivatives as possible antimicrobial agents. Eur J Med Chem 43:155-159
22. Kier LB (1980) Use of molecular negentropy to encode structure governing biological activity. J Pharm Sci 69:807-810
23. Kier LB (1986) Shape indexes of orders. One and three from molecular graphs. Quant Struct Act Relat 5:1-7
24. Kier LB, Hall LH (1983) Estimation of substituent group electronic influence from molecular connectivity delta values. Quant Struct Act Relat 2:163-167
25. Kier LB, Hall LH (1986) Molecular connectivity in structure-activity analysis. Wiley, Chichester, p 262
26. Kier LB, Hall LH (1990) An electrotopological state index for atoms in molecules. Pharm Res 7:801-807
27. Kier LB, Hall LH (1999) Molecular structure description: the electrotopological state. Academic Press, London, p 246
28. Kubinyi H (1994a) Variable selection in QSAR studies I. An evolutionary algorithm. Quant Struct Act Relat 13:285-294
29. Kubinyi H (1994b) Variable selection in QSAR Studies II. A highly efficient combination of systematic search and evolution. Quant Struct Act Relat 13:393-401
30. Lin YM, Flavin MT, Cassidy CS, Mar A, Chen FC (2001) Biflavonoids as novel antituberculosis agents. Bioorg Med Chem Lett 11:2101-2104
31. Lin YM, Zhou Y, Flavin MT, Zhou LM, Nie W, Chen FC (2002) Chalcones and flavonoids as anti-tuberculosis agents. Bioorg Med Chem 10:2795-2802
32. Mandloi D, Joshi S, Khadikar PV, Khosla N (2005) QSAR study on the antibacterial activity of some sulfa drugs: building blockers of Mannich bases. Bioorg Med Chem Lett 15:405-411
33. Nayyar A, Jain R (2005) Recent advances in new structural classes of anti-tuberculosis agents. Curr Med Chem 12:1873-1876
34. O'Brien RJ, Nunn PP (2001) The need for new drugs against tuberculosis. Am J Respir Crit Care Med 163:1055-1058
35. Painea SW, Barton P, Bird J, Denton R, Menochet K, Smith A, Tomkinson NP, Chohan KK (2010) A rapid computational filter for predicting the rate of human renal clearance. J Mol Graph Model 29:529-537
36. Pogliani L (1994) Structure property relationships of amino acids and some dipeptides. Amino Acids 6:141-153
37. Pogliani L (1996) Modeling with special descriptors derived from a medium-sized set of connectivity indices. J Phys Chem 100:18065-18077
38. Prasad YR, Kumar PP, Kumar PR (2008) Synthesis and antimicrobial activity of some new chalcones of 2-acetyl pyridine. Eur J Chem 5:144-148
39. Shapiro S, Guggenheim B (1998) Inhibition of oral bacteria by phenolic compounda. Part. 1. QSAR analysis using molecular connectivity. Quant Struct Act Relat 17:327-337
40. Shivakumar PM, Geetha Babu SM, Mukesh D (2005) QSAR studies on chalcones and flavonoids as antitubercular agents using genetic function approximation (GFA) method. Chem Pharm Bull 55:44-49
41. Smith CV, Sharma V, Sacchettini JC (2004) TB drug discovery: addressing issues of persistence and resistance. Tuberculosis 84:45-55
42. Todeschini R, Consonni V (2001) DRAGON-Software for the calculation of molecular descriptors, rel. 1.12 for Windows
43. Weltman AC, Rose DN (1994) Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. Arch Intern Med 154:2161-2167
44. WHO. WHO Report (2007) http://www.who.int/tb/publications/global-report/ 2007/pdf/full.pdf. Accessed Dec 2010
45. World Health Organization (2003) The WHO Global Tuberculosis Program. http://www.who.int/gtb/. Accessed Sept 2009
46. Yao XJ, Panaye JP, Doucet JP, Zhang RS, Chen HF, Lice MC, Hu ZD, Fan BT (2004) Comparative study of QSAR/QSPR correlations using support vector machines, radial basis function neural networks, and multiple linear regression. J Chem Inf Comput Sci 44:1257-1266
47. Zhoua YP, Cai CB, Huanb S, Jiang JH, Wu HL, Shen GL, Yu RQ (2007) QSAR study of angiotensin II antagonists using robust boosting partial least square regression. Anal Chim Acta 593:68-74